(Q46121646)

19 December 2017

title

Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity (English)

1 reference

19 December 2017

0 references

0 references

3

Artur Antoniewicz

1 reference

19 December 2017

author name string

Marta Ciszewicz

1

1 reference

19 December 2017

Alicja Polubinska

2

1 reference

19 December 2017

Katarzyna Suminska-Jasinska

4

1 reference

19 December 2017

Andrzej Breborowicz

5

1 reference

19 December 2017

publication date

23 January 2009

1 reference

19 December 2017

published in

Translational Research

1 reference

19 December 2017

volume

153

1 reference

19 December 2017

issue

3

1 reference

19 December 2017

page(s)

118-123

1 reference

19 December 2017

Pharmacological actions of sulodexide

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Anti-inflammatory effect of sulodexide during acute peritonitis in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

New potential agents in treating diabetic kidney disease: the fourth act.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Isolated low high density lipoprotein-cholesterol (HDL-C): implications of global risk reduction. Case report and systematic scientific review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Hyperglycemia and the pathobiology of diabetic complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Glucose degradation products (GDP) retard remesothelialization independently of d-glucose concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Sulodexide induces hepatocyte growth factor release in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappaB activation and cytokine expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Heparan sulfate proteoglycans in glomerular inflammation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Heparin effects on superoxide production by neutrophils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Heparin inhibits reactive oxygen species generation by polymorphonuclear and mononuclear leucocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Acute effect of standard heparin versus low molecular weight heparin on oxidative stress and inflammation in hemodialysis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Anti-inflammatory effect of hepatocyte growth factor in chronic kidney disease: targeting the inflamed vascular endothelium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Endothelial dysfunction in normal and abnormal glucose metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Monocyte chemoattractant protein-1--a major contributor to the inflammatory process associated with diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Oxidative stress, AGE, and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

Effect of insulin and heparin on glucose-induced vascular damage in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.12.007

10.1016/J.TRSL.2008.12.007

7 January 2021

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017